Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’ report for the first quarter. The decline in the prescription of Rinvoq and Olumiant was not as big during the period – just under 25 percent of rheumatologists reduced their use of these JAK inhibitors…
